Soleno Therapeutics appoints Jennifer Fulk as CFO, succeeding retiring James Mackaness

SOLENO THERAPEUTICS INC

Jennifer Fulk appointed CFO effective March 2, 2026; base salary $525k, target bonus 45%, option for 67,660 shares, RSUs for 39,200 shares.
James Mackaness retiring by end of March 2026, will consult through December 2026 for smooth transition.
Fulk brings 20+ years experience including 15 years at Eli Lilly, most recently CFO/COO at 120Water and CFO at Talkspace.
Fulk will participate in Soleno's Key Executive Change in Control and Severance Plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.